{
  "id": "mhgap#risk_safety_221e524c",
  "content": "was similar to placebo and quetiapine showed symptoms in adolescents with bipolar disorder\nsignificantly fewer discontinuations than placebo. (current episode depression).\nIn this review, olanzapine caused most weight gain\nResearch gaps\n(not summarized in the evidence profile).\ny Randomized controlled trials are needed,\ny The search process identified one systematic review\nparticularly comparing pharmacological\non acute bipolar mania in children and adolescents,\ninterventions with placebo and with each other, in\nCiray et al., 2020 (11 RCTs, 1974 participants), that\nchildren and adolescents with bipolar disorder in\ncompared different medicines with placebo. Effect\norder to better know their efficacy and safety in this\nsizes by pooling all medicines were moderate (SMD\nvulnerable group.\n= -0.61; 95% CI: -0.78 to -0.44). The certainty of\nevidence was moderate. In the single studies, almost y Further high-quality evidence is required to\nall investigated medicines were superior to placebo understand the use of psychotropic medicines for\n(topiramate, olanzapine, risperidone, aripiprazole, adolescents requiring maintenance treatment.\nziprasidone, quetiapine, asenapine, lithium). The y Ciray et al., 2020 investigated no side-effects. More\nmost efficacious medicine was risperidone. As research is needed to investigate side-effects of\nexpected, there were side-effects such as weight- medicines in this age group (201).",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "risk_safety",
      "screening_cues",
      "management"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General — Risk Safety was similar to placebo and quetiapine showed symptoms in adolescents with bipolar disorder\nsignificantly fewer discontinuations than placebo. (current episode depression).\nIn this review, olanzapine caused most weight gain\nResearch gaps\n(not summarized in the evidence profile).\ny Randomized controlled trials are needed,\ny The search process identified one systematic review\nparticularly comparing pharmacological\non acute bipolar mania in children and adolescents,\ninterventions with placebo and with each other, in\nCiray et al., 2020 (11 RCTs, 1974 participants), that\nchildren and adolescents with bipolar disorder in\ncompared different medicines with placebo. Effect\norder to better know their efficacy and safety in this\nsizes by pooling all medicines were moderate (SMD\nvulnerable group.\n= -0.61; 95% CI: -0.78 to -0.44). The certainty of\nevidence was moderate. In the single studies, almost y Further high-quality evidence is required to\nall investigated medicines were superior to placebo understand the use of psychotropic medicines for\n(topiramate, olanzapine, risperidone, aripiprazole, adolescents requiring maintenance treatment.\nziprasidone, quetiapine, asenapine, lithium). The y Ciray et al., 2020 investigated no side-effects. More\nmost efficacious medicine was risperidone. As research is needed to investigate side-effects of\nexpected, there were side-effects such as weight- medicines in this age group (201). Was similar to placebo and quetiapine showed symptoms in adolescents with bipolar disorder\nsignificantly fewer discontinuations than placebo. (current episode trầm cảm)."
}